Patent · US Active

Fibronectin binding domains with reduced immunogenicity

US9765132B2 · kind B2 · utility

8Cited by

29References

46Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

Jonathan Davis · Waltham, US
Dasa Lipovsek · Pepperell, US
Ray Camphausen · Wayland, US

Key dates

Filing date	Feb 1, 2013
Grant date	Sep 19, 2017
Priority date	—
Expiry date	Jun 20, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC40B40/10
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.